A comparative study of cyclophosphamide versus tacrolimus based therapy in membranous glomerulonephritis.
Phase 4
Completed
- Conditions
- Health Condition 1: null- Idiopathic Membranous glomerulonephritis
- Registration Number
- CTRI/2013/10/004061
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
1.Biopsy proven idiopathic membranous nephropathy
2.Nephrotic syndrome with proteinuria ( >4 gm/day) or >=2.0 gm/day along with serum albumin <2.5gm/dl
3.At least 6 months on ACEi or ARBs treatment or anyone with severe complicated nephrotic syndrome
4.Age 18-60 yrs with informed consent
Exclusion Criteria
1.Serum creatinine >2.5mg/dl
2.Patients with abnormal liver function tests and diabetes mellitus
3.Active infection
4.Patient with prior therapy with steroids, cyclophosphamide, sirolimus, CSA, MMF, azathioprine and rituximab.
5.Patients with secondary cause
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients achieving complete remission and partial remissionTimepoint: 6 and 12 months
- Secondary Outcome Measures
Name Time Method Estimated GFR (eGFR) as measured by MDRD and adverse eventsTimepoint: at 6 and 12 months of treatment completion